Stem Cell Therapy Market

The stem cell therapy market is projected to reach USD 3.65 billion by 2035 from USD 0.48 billion in 2026, at a CAGR of 25.3%. The market is driven by the increasing prevalence of chronic and degenerative diseases, rising investments in regenerative medicine, and expanding clinical trial activities for stem cell-based therapies. Additionally, advancements in induced pluripotent stem cell (iPSC) technologies and the broader adoption of allogeneic stem cell therapy platforms are expected to support market growth.

The global stem cell therapy market is consolidated, with top players such as Vericel Corporation (US), Mesoblast (Australia), MEDIPOST (South Korea), JCR Pharmaceuticals Co., Ltd (Japan), Takeda Pharmaceutical Company Limited (Japan), and Anterogen Co., Ltd. (South Korea) leading the market. The market players have adopted various strategies, including approvals and product and service launches, acquisitions, agreements, collaborations, partnerships, and geographic expansions, to strengthen their position in the global stem cell therapy market.

To know about the assumptions considered for the study download the pdf brochure

In February 2026, MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced that it had filed an Investigational New Drug (IND) amendment to the US Food and Drug Administration (FDA) to support the initiation of a Phase III clinical trial evaluating its investigational cell therapy for knee osteoarthritis.

Vericel Corporation (US)

Vericel Corporation is a leading participant in the broader stem cell therapy and regenerative cell therapy market, supported by its focused portfolio of advanced autologous cell-based products for orthopedic and severe burn care applications. The company’s key commercial products include MACI, an autologous cellularized scaffold product used for the repair of symptomatic full-thickness cartilage defects of the knee in adults, and Epicel, an autologous cultured epidermal graft used for patients with severe burns.

Mesoblast (Australia)

Mesoblast is a prominent player in the stem cell therapy market, with a strong focus on allogeneic mesenchymal stromal cell therapies for inflammatory, immune-mediated, and degenerative diseases. The company’s key marketed product is Ryoncil / remestemcel-L-rknd, an allogeneic bone marrow-derived mesenchymal stromal cell therapy approved by the FDA for pediatric patients with steroid-refractory acute graft-versus-host disease. This approval is a major milestone for the stem cell therapy market, as Ryoncil became the first FDA-approved mesenchymal stromal cell therapy, validating MSCs as a commercially viable therapeutic class.

JCR Pharmaceuticals Co., Ltd (Japan)

JCR Pharmaceuticals is a key participant in the stem cell therapy market through its development and commercialization of TEMCELL HS (temisirolomucel-L), a bone marrow-derived mesenchymal stem cell product approved for graft-versus-host disease (GvHD). The company supports therapeutic development and commercial manufacturing workflows with integrated cell processing technologies and continued expansion in regenerative medicine and cell therapy sciences.

Market Ranking

The stem cell therapy market is characterized by moderate to high consolidation, with leading players accounting for a major share of global market revenues. These major companies strengthen their market positions through strategic acquisitions, expansion of manufacturing capabilities, regulatory approvals, clinical pipeline development, and broad product portfolios spanning approved therapies and pipeline candidates.

Vericel Corporation (US) offers a comprehensive regenerative medicine portfolio, including advanced orthopedic solutions that leverage stem cell and tissue engineering technologies to support musculoskeletal and wound healing applications. MEDIPOST (South Korea) provides innovative cord blood-derived mesenchymal stem cell therapeutics, including CARTISTEM for cartilage repair, supporting regenerative treatment across orthopedic and degenerative conditions. JCR Pharmaceuticals (Japan), through its TEMCELL HS product, delivers bone marrow-derived mesenchymal stem cell therapy solutions for graft-versus-host disease, with ongoing clinical development across additional therapeutic indications. Takeda Pharmaceutical Company (Japan) focuses on advancing stem cell-based therapies through strategic collaborations and pipeline investments, leveraging its global infrastructure to accelerate regenerative medicine development across multiple therapeutic areas.

The remainder of the market consists of emerging biotechnology companies, specialty clinics, and regional players. These players are expanding through targeted innovation, clinical trial advancements, localized collaborations, and customized stem cell therapy solutions tailored to hospitals, specialty clinics, academic institutions, and contract development and manufacturing organizations (CDMOs) requiring flexible and application-specific treatment capabilities.

Related Reports:

Stem Cell Therapy Market by Cell Source (Adipose Tissue, Bone Marrow, Placenta, Umbilical Cord, iPSC), Type (Autologus Stem Cell), Therapeutic Application (Musculoskeletal, Wounds, Surgeries, Cardiovascular, Neurological), End User - Global Forecast to 2035

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]